TELERETINODIAB: MONITORING OF MODERATE DIABETIC RETINOPATHY BY TELE-EXPERTISE

Sponsor
Centre Hospitalier Sud Francilien (Other)
Overall Status
Recruiting
CT.gov ID
NCT03437018
Collaborator
(none)
150
1
40
3.7

Study Details

Study Description

Brief Summary

The aim of this study is to evaluate the monitoring of moderate diabetic retinopathy by tele-expertise

Condition or Disease Intervention/Treatment Phase
  • Other: moderate diabetic retinopathy follow-up by tele-expertise

Detailed Description

This study compares 2 strategies of monitoring of moderate diabetic retinopathy (RD).After a consultation with an orthoptist for measurement of visual acuity, measurement of ocular tone by pulsed air tonometer, retinography pictures (9 photographs: one of the posterior pole and 8 of the retinal periphery) and Optical Coherence Tomography (OCT), results are evaluated on-site by an ophthalmologist and then sent through a secure medical online application to an ophthalmologist expert in RD for assessment. Each patient is his own control.

Study Design

Study Type:
Observational
Anticipated Enrollment :
150 participants
Observational Model:
Case-Crossover
Time Perspective:
Prospective
Official Title:
COMPARISON OF MONITORING OF MODERATE DIABETIC RETINOPATHY BY TELE-EXPERTISE AND CONVENTIONAL OPHTHALMOLOGICAL CONSULTATION
Actual Study Start Date :
Oct 14, 2019
Anticipated Primary Completion Date :
Jan 13, 2023
Anticipated Study Completion Date :
Feb 13, 2023

Outcome Measures

Primary Outcome Measures

  1. classification of diabetic retinopathy (DR) [1 month]

    DR is classified in 3 stages : moderate non proliferative DR, severe non proliferative DR, and proliferative DR

Secondary Outcome Measures

  1. classification of macular edema [1 month]

    macular edema (ME) is classified in 4 stages : no ME , mild ME, moderate ME, severe ME

  2. follow-up strategy [1 month]

    follow-up strategy can take to ways : no treatment required and continuation of the monitoring/ complementary exam or treatment required

  3. medical time necessary for examination and analyse [1 month]

    time necessary for direct examination and analyse by ophthalmologist on-site and time necessary for remote analyse are measured

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • patient with complicated diabetes mellitus with moderate retinopathy
Exclusion Criteria:
  • Patient deprived of liberty by judicial or administrative decision

  • Person subject to a legal protection measure

  • Patient already involved in another clinical trial protocol

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier Sud Francilien Corbeil-Essonnes France 91106

Sponsors and Collaborators

  • Centre Hospitalier Sud Francilien

Investigators

  • Principal Investigator: Alfred Penfornis, Centre Hospitalier Sud Francilien

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Centre Hospitalier Sud Francilien
ClinicalTrials.gov Identifier:
NCT03437018
Other Study ID Numbers:
  • ID RCB 2017-A02329-44
First Posted:
Feb 19, 2018
Last Update Posted:
Jan 28, 2022
Last Verified:
Jan 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Sud Francilien
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 28, 2022